Industry

LimX Dynamics Raises $200M Pre-IPO at About $2.2B Valuation

Robb Harlan 4 min read

LimX Dynamics is treating a public listing like a survival skill. The Shenzhen humanoid startup said it closed a US$200 million pre-IPO round that values the company at 15 billion yuan — about $2.21 billion on CNBC’s math, $2.2 billion in Nikkei’s write-up — and is already in a confidential review phase for an IPO, likely in Hong Kong.

Founder Will Zhang told reporters, per CNBC: “Listing is a must,” comparing the moment to Chinese EV startups that went public once the tech was “mature enough” — or risked fading.

LimX Dynamics humanoid robot Oli at Shenzhen headquarters
LimX’s Oli humanoid at company headquarters in Shenzhen, July 3, 2026. Source: Nikkei Asia / Wataru Suzuki.

Who Wrote the Check

According to CNBC’s report on the company’s release, overseas participants included Stone Venture (UAE), GGG (Italy), and Redstone VC (Germany). Domestic and strategic names listed: Lens Technology, IDG Capital, WestSummit Capital, Nio Capital, and Hefei Binhu Industry Development Group.

The wider context is a funding spike. CNBC cited industry data provider Xiniu: China humanoid-sector investment hit 47.09 billion yuan (~$6.95B) in Q2 — more than double Q1 and over six times the year-ago quarter. Unitree’s Shanghai fast-track and a thick Hong Kong queue sit in the same story.

What LimX Is Selling

Company product pages describe Oli as a 165 cm, 31-DoF full-size general-purpose humanoid with modular end-effectors, quick-swap batteries, depth cameras, and dual compute for motion and perception. CNBC says LimX is aiming at fully autonomous commercial service robots, a multi-year plan to ship thousands of humanoids to the Middle East, and deliveries of entertainment-focused Luna units to South Korea customers.

LimX Oli full-size humanoid robot product imagery
Oli product still from LimX Dynamics’ official product page. Source: LimX Dynamics.

Zhang’s strategic line, via CNBC: the “0 to 1” invention phase is done; the next moat is a product that meets user needs — and capital markets that can fund that grind.

A Human’s Take

Pre-IPO at $2B+ with Middle East and Korea shipment talk is a scale bet, not a lab bet. I’ll believe the autonomy pitch when deployment data is public; until then, the hard news is the raise, the valuation, and the listing process. Unitree’s Shanghai path raises the competitive pressure on every peer still private. Filing day is the next real chapter.

Sources